A Study of Cytisinicline for Vaping Cessation in Adult Smokers

Phase 2 Completed 160 enrolled Achieve Life Sciences

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.

Timeline

Start: 2022-07-13
Primary completion: 2023-02-28
Completion: 2023-02-28

Publications

Rigotti NA, Benowitz NL, Prochaska JJ, Cain DF, Ball J, Clarke A, Blumenstein BA, Jacobs C. Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial. JAMA Intern Med. 2024 Aug 1;184(8):922-930. doi: 10.1001/jamainternmed.2024.1313.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytisinicline	Small molecule	3 mg	Oral

Indications

No indication recorded.